✨ Onyx Summary enGene Holdings granted inducement equity awards totaling 93,200 stock options to three new employees, with an exercise price of $3.79 per share and a four-year vesting schedule. The grants, made under Nasdaq Listing Rule 5635(c)(4), align new hires’ incentives with shareholder interests as the
✨ Onyx Summary Belite Bio said China’s NMPA has accepted, with priority review, its NDA for Tinlarebant in Stargardt disease based on interim Phase 3 DRAGON results showing statistical significance on the primary endpoint. If approved, Tinlarebant would become the first therapy for Stargardt; Belite plans to report final topline
✨ Onyx Summary SpyGlass Pharma reported 24-month interim results from its first-in-human trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), showing a 42% mean reduction in intraocular pressure and elimination of all topical medications in patients with open-angle glaucoma or ocular hypertension. The device demonstrated durable efficacy, safety, and improved
✨ Onyx Summary Alzheon announced the peer-reviewed publication of results from its pivotal Phase 3 APOLLOE4 trial evaluating oral valiltramiprosate (ALZ-801) in APOE4/4 homozygous individuals with early Alzheimer’s disease, showing cognitive and functional benefits in patients at the mild cognitive impairment stage, along with neuroprotective effects on brain atrophy
✨ Onyx Summary Piramal Pharma Solutions and NewAmsterdam Pharma announced a multi-million-dollar investment to establish a dedicated oral solid dosage suite at Piramal’s Sellersville, Pennsylvania site, enhancing production capacity for NewAmsterdam’s fixed-dose combination of obicetrapib and ezetimibe. The initiative expands Piramal’s integrated CDMO network, supports future commercial demand
✨ Onyx Summary Lexicon Pharmaceuticals presented new Phase 2 analyses for pilavapadin (LX9211) at the 19th Annual Pain Therapeutics Summit, confirming the 10 mg once-daily dose as the optimal candidate for Phase 3 development in diabetic peripheral neuropathic pain (DPNP). The findings—demonstrating validated biological activity, clinically meaningful pain reduction, and
✨ Onyx Summary Affinia Therapeutics CEO Rick Modi will participate in a panel on in vivo gene therapies for genetic cardiac diseases at Chardan’s 9th Annual Genetic Medicines Conference on Oct. 21 and hold one-on-one investor meetings at the Jefferies Global Healthcare Conference in London on Nov. 17–20. The
✨ Onyx Summary Rocket Pharmaceuticals announced that the U.S. FDA has accepted its resubmitted BLA for KRESLADI™ (marnetegragene autotemcel; marne-cel), an investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I), setting a PDUFA date of March 28, 2026. The filing is supported by Phase 1/2 data showing 100% survival
✨ Onyx Summary Verily has entered a multi-year strategic collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience to advance precision medicine through AI-driven data integration and analytics on Verily’s healthcare technology platform. The partnership will create AI-ready biomedical data pipelines, develop novel models across major therapeutic areas, and
✨ Onyx Summary Geron Corporation announced multiple leadership changes to align with its commercial growth strategy, including the appointment of Ahmed ElNawawi as EVP and Chief Commercial Officer, alongside new senior hires in technical operations, investor relations, and portfolio management. These appointments strengthen Geron’s leadership capabilities as it drives commercialization
✨ Onyx Summary Avidity Biosciences completed a positive pre-BLA meeting with the U.S. FDA for delpacibart zotadirsen (del-zota), its investigational Duchenne muscular dystrophy (DMD44) therapy, and now plans to file the BLA in Q1 2026 to include additional CMC data. The company’s first planned BLA submission marks a key
✨ Onyx Summary Seer, Inc. announced its participation at the 2025 American Society of Human Genetics Annual Meeting, where it will showcase how its Proteograph® Product Suite enables integration of proteomics and genomics to advance precision medicine. The company will host a featured CoLab session and support multiple scientific presentations demonstrating
✨ Onyx Summary Rocket Pharmaceuticals granted inducement equity awards to newly appointed Chief Medical Officer Dr. Syed Rizvi, consisting of stock options and restricted stock units totaling approximately 729,765 shares. The awards, approved under Nasdaq’s inducement grant rule, align long-term incentives with Rocket’s strategic growth as it advances
✨ Onyx Summary Lexicon Pharmaceuticals hosted a policy roundtable in Washington, DC, bringing together clinicians, patient advocates, and industry experts to discuss expanding the scope of the federal “Alternatives to PAIN Act” to include chronic pain sufferers, beyond its current focus on acute and post-surgical pain. CEO Mike Exton emphasized the
✨ Onyx Summary Lexicon Pharmaceuticals convened a policy roundtable in Washington, D.C., with clinicians, advocates, and patients to discuss expanding the Alternatives to PAIN Act to include chronic pain patients under Medicare Part D coverage for non-opioid treatments. The company plans to publish a White Paper summarizing insights from the
✨ Onyx Summary Affinia Therapeutics closed a $40 million Series C financing led by NEA with participation from Eli Lilly and existing investors to advance its lead gene therapy candidate AFTX-201 for BAG3 dilated cardiomyopathy (DCM). The proceeds will support IND submission in Q4 2025 and initiation of the Phase 1/
